SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 8-K
Document Type: EX-99.1
Date Filed: 2026-05-14
Accession Number: 0001213900-26-056244
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390026056244/ea029076501ex99-1.htm

Chunk 1 of 2
Word Count: 670
Character Count: 4657

Document Content:

85,811 88,108 Contract liabilities - 1,526 Short term loans payable, net of debt discount, related party - 100,000 Current portion of notes payable, net of debt discount 2,730,981 1,658,215 Total Current Liabilities 6,848,786 8,236,068 Long-term Liabilities: Notes payable, net of debt discount 25,018,055 25,056,446 Total long-term liabilities 25,018,055 25,056,446 Total Liabilities 31,866,841 33,292,514 Commitments and contingencies Stockholders’ Deficit: Common stock, $0.00001 par value; 300,000,000 shares authorized; 11,483,926 shares issued; 11,303,853 outstanding 114 114 Additional paid in capital 33,710,857 33,594,550 Common stock to be issued 153,400 - Accumulated other comprehensive loss (132,201 ) (154,281 ) Accumulated deficit (59,009,920 ) (56,441,021 ) Less: Treasury stock (180,073 shares) at cost (127,500 ) (127,500 ) Total stockholders’ deficit (25,405,250 ) (23,128,138 ) Total Liabilities and Stockholders’ Deficit $ 6,461,591 $ 10,164,376 Synergy CHC Corp. Unaudited Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income For the three months ended For the three months ended

March 31,
2026 March 31,

Revenue

Product Sales $	5,492,705 $	6,670,534

License Revenue - 1,500,000

Total Revenue 5,492,705 8,170,534

Cost of Sales 1,521,910 2,006,513

Gross Profit 3,970,795 6,164,021

Operating expenses

Selling and marketing 2,455,732 2,876,271

General and administrative 2,048,850 1,306,714

Depreciation and amortization 33,333 33,333

Total operating expenses 4,537,915 4,216,318

(Loss) Income from operations (567,120	) 1,947,703

Other (income) expenses

Interest income (340	) (13,882	)

Interest expense 2,012,121 1,095,369

Remeasurement loss on translation of foreign subsidiary 3,718 1,412

Total other expenses 2,015,499 1,082,899

Net (loss) income before income taxes (2,582,619	) 864,804

Income tax benefit 13,720 11,460

Net (loss) income after tax $	(2,568,899	) $	876,264

Net (loss) income per share – basic $	(0.23	) $	0.10

Net (loss) income per share – diluted $	(0.23	) $	0.10

Weighted average common shares outstanding

Basic 11,303,853 8,560,636

Diluted 11,303,853 8,577,620

Comprehensive (loss) income:

Net (loss) income $	(2,568,899	) $	876,264

Foreign currency translation adjustment 22,080 (1,935	)

Comprehensive (loss) income $	(2,546,819	) $	874,329

Synergy CHC Corp.

Unaudited Condensed Consolidated Statements of
Cash Flows

For the three months ended For the three months ended

March 31,
2026 March 31,

Cash Flows from Operating Activities

Net (loss) income $	(2,568,899	) $	876,264

Adjustments to reconcile net (loss) income to net cash used in operating activities:

Amortization of debt discount and debt issuance cost 951,942 406,841

Depreciation and amortization 33,333 33,333

Stock based compensation 116,307 -

Foreign currency transaction loss (gain) 2,684 (3,137	)

Remeasurement loss (gain) on translation of foreign subsidiary 3,718 (1,412	)

Changes in operating assets and liabilities:

Accounts receivable 1,935,483 940,519

Other receivables - 144,637

Loan receivable, related party - (833	)

Inventory 355,895 (629,935	)

Prepaid expenses (410,657	) (114,787	)

Prepaid expense, related party (541,467	) (195,913	)

Income taxes payable (2,297	) (165,413	)

Contract liabilities (1,526	) (24,216	)

Accounts payable and accrued liabilities (1,915,323	) (2,218,041	)

Accounts payable, related party (3,871	) 129,312

Net cash used in operating activities (2,044,678	) (822,781	)

Cash Flows from Investing Activities - -

Cash Flows from Financing Activities

Advances from related party - 135,000

Repayment of notes payable, related party (100,000	) -

Proceeds from notes payable 2,660,000 1,496,250

Payment of loan financing fees (55,000	) -

Repayment of notes payable (2,812,600	) (1,316,572	)

Net cash (used in) provided by financing activities (307,600	) 314,678

Effect of exchange rate on cash, cash equivalents and restricted cash 22,080 (1,935	)

Net decrease in cash, cash equivalents and restricted cash (2,330,198	) (510,038	)

Cash and restricted cash, beginning of year 2,722,313 787,920

Cash and restricted cash, end of period $	392,115 $	277,882

Supplemental Disclosure of Cash Flow Information:

Cash paid during the period for:

Interest $	392,846 $	573,529

Income taxes $	- $	-

Supplemental Disclosure of Noncash Investing and Financing Activities:

Issuance of common stock for accounts receivable advance financing $	- $	117,648

Loan financing fees, accrued $	110,000 $	-

Capitalized interest on senior debt $	400,033 $	-

Common stock to be issued for accounts receivable advance financing $	153,400 $	-